AGP Executive Report

In the last 12 hours, the most concrete industry-relevant update is a corporate/biopharma development: Pharming Group reported preliminary Q1 2026 results, with total revenues of US$72.4m (down 8% YoY) driven by RUCONEST® revenue of US$58.4m (down 15%) amid “anticipated inventory drawdowns” and a planned exit from non-U.S. markets. Offsetting this, Joenja® revenue rose to US$14.1m (up 34%), described as reflecting strong patient uptake and momentum. The company also highlighted regulatory progress (including Japan approval and a positive CHMP opinion for APDS) and FDA resubmissions for pediatric sNDA for Joenja® highest doses, with plans for additional filings for lowest doses. (A separate “webinar” page appears in the feed but contains no substantive industry content beyond a technical “watch now” error.)

Broader “industry context” in the same 12-hour window is thinner, but the feed includes a global media freedom commentary (World Press Freedom Day) and a travel/tourism item about Bosnia and Herzegovina’s social-media-driven destination engagement—neither directly tied to Liechtenstein industry, but both reflect the wider information and tourism environment in which businesses operate. The remaining 12–24 hour items are also largely non-Liechtenstein-specific, including a sports feature and a press-freedom critique.

From 12 to 24 hours ago, the Pharming update is echoed by the same Q1 results coverage (with additional detail that it is “on track” for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026). The rest of that band is dominated by non-industry headlines (e.g., “The press in distress”), so the main continuity signal is that Pharming’s Joenja® growth and pediatric regulatory pathway remain the standout business thread.

Looking back 3–7 days, the feed provides supporting background on cross-border economic and regulatory themes that can matter to Liechtenstein-based firms, but without direct Liechtenstein-specific industrial outcomes. Examples include EU sanctions enforcement coordination (explicitly listing partners including Liechtenstein), EU border-check policy shifts affecting Schengen travel flows (with Liechtenstein mentioned as part of the Schengen coverage in one item), and trade/industrial policy narratives such as the EU’s “Made in Europe” approach in response to China and the Mercosur–EU trade deal entering provisional application. There is also a clear technology/industry-adjacent thread in the older material: electric vehicle market weakness globally (with Europe still showing growth) and Hilti India’s academia–industry lab collaboration—useful as signals of where industrial investment and demand pressures are moving, even though they are not directly tied to Liechtenstein.

In the last 12 hours, the most substantive industry-relevant development is Pharming Group’s preliminary Q1 2026 results. The company reported total revenues of US$72.4 million (down 8% year-on-year), with RUCONEST® at US$58.4 million (down 15%) attributed to anticipated inventory drawdowns and a planned exit from non-U.S. markets. Offsetting this, Joenja® revenue rose 34% to US$14.1 million, driven by patient uptake, and Pharming reiterated 2026 revenue guidance of US$405–US$425 million. The update also highlights ongoing regulatory momentum for Joenja® (Japan approval and a positive CHMP opinion for APDS), alongside FDA resubmissions for pediatric dosing tiers, and a scheduled conference call.

Also in the last 12 hours, coverage is lighter and more mixed in relevance to Liechtenstein’s industrial/financial ecosystem: a sports-focused piece on Bristol Rovers’ 2025/26 season player ratings, and a commentary on World Press Freedom Day and the state of global press freedom. The remaining “last 12 hours” items are more editorial than policy or market-moving, so they provide limited direct continuity for industry themes.

From 12 to 72 hours ago, the coverage becomes more policy- and market-oriented, with several items that indirectly matter for cross-border business conditions. EU travel and border administration appears repeatedly: Italy and Portugal are described as preparing to scrap new EU border checks after Greece’s suspension of EES biometric requirements for UK tourists, with concerns raised that abandoning checks could undermine the broader EES rollout. In parallel, EU-level regulatory coordination is covered via the European Commission welcoming approval of revised social security coordination rules, aimed at reducing administrative burdens and improving protection for people working or living across EU borders—an issue that can affect labor mobility and cross-border company operations.

Across the broader 7-day window, there is also clear continuity around Liechtenstein-adjacent finance and trade themes. A CEO Insight supplement includes an interview with Simon Tribelhorn of the Liechtenstein Bankers Association, framing Liechtenstein’s positioning around legal certainty, cross-border capability, and balancing innovation (including digital assets and sustainability) with trust and regulatory strength. On the trade side, multiple articles discuss EU external economic policy and market access dynamics—such as the “Made in Europe” law concept tied to an economic showdown with China, and the Mercosur–EU trade deal entering provisional application with tariff cuts on thousands of products—while sanctions enforcement against Russia is also highlighted as being intensified with coordination including Liechtenstein.

Overall, the most concrete “industry” signal in the most recent window is Pharming’s Q1 performance and regulatory pathway for Joenja®, while the rest of the latest coverage is dominated by travel/border administration and broader geopolitical/economic commentary. The evidence is strong for Pharming’s near-term corporate trajectory, but comparatively sparse for any single Liechtenstein-specific industrial event in the last 12 hours.

In the last 12 hours, coverage is dominated by broad, policy-leaning commentary rather than Liechtenstein-specific industrial developments. One piece argues Europe’s “big problem” is political shortsightedness and bellicosity, while also pointing to a “recipe” for small European states (including Liechtenstein) built around neutrality, low taxes, light bureaucracy, and free trade. Another article frames Europe’s near-term strategic risk in terms of NATO durability and the potential for renewed nationalism and conflict if the U.S. role shifts—explicitly tying the discussion to the Iran war’s effects on oil prices and European security calculations. Together, these suggest the editorial focus is on geopolitical uncertainty and Europe’s economic-policy direction, with no clear new industrial policy or company-level change evidenced in the most recent texts.

Across the broader 7-day window, several items connect directly to European economic competitiveness and cross-border rules that can affect industry and investment. EU-level policy updates include the European Commission welcoming approval of revised social security coordination rules, aimed at “fair labour mobility” and reduced administrative burden for cross-border employers and workers. In parallel, multiple reports describe the EU’s Entry/Exit System (EES) rollout problems and a growing “domino effect” of suspensions: Greece first paused biometric checks for UK tourists, and Portugal and Italy are preparing to follow, with industry insiders warning that abandoning checks could undermine the EES framework. This cluster is one of the clearest “operational” themes in the dataset, even if it is travel-focused rather than industrial per se.

Trade and industrial competitiveness themes also recur. A “Made in Europe” law (“Industrial Accelerator Act”) is described as setting the stage for an economic showdown with China, in the context of EU tariffs on Chinese EVs and ongoing dispute dynamics. Separately, the Mercosur–EU trade deal is reported as entering provisional application on May 1, with tariff elimination on more than 5,000 Brazilian product categories—an event that can matter for European manufacturing supply chains and input costs, though the provided evidence is limited to headline tariff figures and “day one” framing. On the technology/industry side, electric vehicle market coverage is mixed: one report says global EV sales weakened in Q1 due largely to weak demand in China, while another notes that BEV registrations in Europe and EFTA rose sharply in early 2026, attributing momentum partly to higher gasoline prices and incentives.

Finally, several items touch on finance, innovation, and regional economic positioning that are relevant to Liechtenstein’s broader ecosystem. A CEO Insight supplement highlights Liechtenstein’s positioning as a financial centre built on legal certainty and cross-border capability, while also referencing balancing innovation (including digital assets and sustainability) with trust and regulatory strength. There is also continuity around Liechtenstein’s presence in European coordination and mobility contexts (e.g., EFTA-related trade dialogue and visa-free lists that include Liechtenstein), but the evidence is largely informational rather than indicating a new Liechtenstein industrial initiative. Overall, the most recent 12-hour evidence is sparse and mostly geopolitical/commentary-driven, while the strongest “industry-adjacent” signals in the week come from EU rule changes (social security coordination, EES suspensions) and trade/competitiveness developments (China/EU industrial policy, Mercosur–EU tariff cuts).